Avandia Settlements Reported   May 10, 2010

Today it was reported that GSK has settled more than 700 Avandia cases for a sum reported to be approximately 60 million dollars. These are the first reported settlements involving the drug and represent a small fraction of the total claims believed to be pending. The average settlement would appear to be around 90-95 thousand dollars per case. Read more »

Filed under:
Avandia Statute of Limitations May Expire for Residents of 18 States   March 24, 2010

Diabetics from 18 states who suffered heart attacks or other cardiovascular injuries while taking Avandia only have a short time left to file a claim for compensation. The right to file a claim for compensation is subject to a statute of limitations. Read more »

Filed under:
Saudi FDA Removes Avandia From the Market   March 22, 2010

According to a Dow Jones report, Saudi Arabia has suspended GlaxoSmithKline PLC's (GSK) diabetes drug Avandia from the market for six months. The Saudi authorities found that Avandia's heart risks did not outweigh its benefits. Read more »

Filed under:
Mayo Clinic Reports That Scientists Who Supported Avandia Had Financial Ties To Glaxo   March 21, 2010

In a study published in the British Medical Journal, researchers from the Mayo Clinic after examining more than 200 articles addressing the safety and efficacy of Avandia concluded that, "[a]uthors who had favourable views on the safety of rosiglitazone were more likely to have a financial conflict of intere Read more »

Filed under:
GlaxoSmithKline's RECORD study flawed, experts say.   June 9, 2009

A GlaxoSmithKline funded study called RECORD, which allegedly exculpated the pill from increasing the risk of cardiovascular disease, was labeled by some physicians as “flawed” and the study cannot l Continue reading ⇒

Filed under:
Results of RECORD Avandia study presented to the American Diabetes Association   June 5, 2009

The results of the RECORD study was presented at the American Diabetes Association meeting in New Orleans. Continue reading ⇒

Filed under:
New study to analyze effects of diabetes drug Avandia initiated.   June 4, 2009

Drug side effects many times cannot be determined when the drug is approved. They can only be found after millions of people use the drugs and report the results.  Continue reading ⇒

Filed under:
AVANDIA (ROSIGLITAZONE) AND CARDIOVASCULAR RISK   September 18, 2007

Avandia (generically known as rosiglitazone) is a form of thiazolidinedione drug commonly used to lower blood glucose levels in patients with type 2 diabetes. Thiazolideinesdiones, prescribed in normal doses, decrease glycated hemoglobin levels by an average of about 1 one percentage point or less. Continue reading ⇒

AVANDIA vs. ACTOS - The Winner Is!   September 18, 2007

The Cleveland Clinic has found that while Avandia increases tthe risks of heart attack, stroke and death, its chief competitior Actos, lowers the risk of heart attack, stroke and death in patients who use Actos to manage diabetes.  Continue reading ⇒

Avandia Linked to PPH/PAH   September 18, 2007

Avandia a drug manufactured by GlaxoSmithKine for the treatment of Type II Diabetes has been linked to several heart related adverse events including cases of primary pulmonary hypertension, PAH, heart attacks, strokes, congestive heart failure, edema and fluid retention. Prior claims that the drug was heart protective seem to be untrue. Continue reading ⇒

Filed under:

Lawsuits of Interest

Accutane  (isotretinoin)
Advair  (Fluticasone/salmeterol)
Arthritis Drugs
Asbestos / Mesothelioma
Avandia  (Rosiglitazone)
Bextra  (Valdecoxib)
Celebrex  (Celecoxib)
Chantix  (Varenicline)
Denture Cream
Digitek  (Digoxin)
Digoxin
Elidel  (Pimecrolimus)
Fentanyl Patch
Fosamax
Gadolinium

Fill out this form for a free evaluation:
Please type your name.
Please type your email address.
Please select the cause of your injury.
Enter any information that you would lke us to know.